Skip to main content
. Author manuscript; available in PMC: 2019 May 1.
Published in final edited form as: Hum Immunol. 2017 Nov 22;79(5):258–265. doi: 10.1016/j.humimm.2017.11.008

Table 1.

The summary of clinical experience.

# Protocol Transient chimerism Engraftment syndrome Outcome I.S. free graft survival
1 NKD03 + No rejection > 13 years
2 NKD03 + + MPGN recurrence 7 years
3 NKD03 + + AHR on day 10 (Pre-sensitized)
4 Mod NKD03 + + Chronic rejection after 5 years 4 years
5 Mod NKD03 + + Chronic rejection after 7 years 6 years
6 ITN036 + + No rejection > 7.2 years
7 ITN036 + + No rejection > 7 years
8 ITN036 + + Lost graft 6 month due to TMA
9 ITN036 + + No rejection > 6.8 years
10 ITN036 + + Acute rejection 2 months
11 TBI/aCD2 + No rejection > 2.5 years
12 TBI/aCD2 Stable under I.S. Under I.S.

I.S.:immunosuppression, TBI: Total Body Irradiation.